Work

488P Phase I trial of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in follicular lymphoma (FL), small cell lung cancer (SCLC) and castration-resistant prostate cancer (CRPC)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.07.616

Authors: M. Schweizer, K.D. Penkov, A.W. Tolcher, A.D. Choudhury, V. Doronin, R. Aljumaily, E. Calvo, R.C. Frank, J.T. Hamm, V. Moreno Garcia, V. Vorobyev, S. Billotte, T. Bowler, J. Chen, T. Lin, L. Liu, A. Maity, S. Sharma, M.L. Johnson

Institutions: University of Washington, Dana-Farber Cancer Institute, Moscow Multidisciplinary Clinical Center "Kommunarka", OU Health Stephenson Cancer Center, University of Oklahoma, Norwalk Hospital, Nuvance Health, Norton Healthcare, Hospital Universitario Fundación Jiménez Díaz, Botkin Hospital, Pfizer (United States), Tennessee Oncology

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4296008626

FWCI: 0.703

Cites:

Cited by: 6

Related to: 10